Close menu




April 4th, 2023 | 17:04 CEST

Race against cancer: BioNTech, Bayer, Defence Therapeutics

  • Biotechnology
  • Cancer
Photo credits: pixabay.com

BioNTech first became known to the general public about three years ago. At that time, the pandemic was rampant and the first vaccine plans were making the rounds in the media. Among all the big names, BioNTech was initially one of many options for the public. In the meantime, the Company has become so dominant in Germany that the competition has been left behind. We look at what this means for investors and the pharmaceutical industry.

time to read: 3 minutes | Author: Nico Popp
ISIN: BIONTECH SE SPON. ADRS 1 | US09075V1026 , BAYER AG NA O.N. | DE000BAY0017 , DEFENCE THERAPEUTICS INC | CA24463V1013

Table of contents:


    Sébastien Plouffe, CEO, Founder and Director, Defence Therapeutics Inc.
    "[...] Defence will continue to develop its Antibody Drug Conjugates "ADC" and its radiopharmaceuticals programs, which are currently two of the hottest products in demand in the pharma industries where significant consolidations and take-overs occurred. [...]" Sébastien Plouffe, CEO, Founder and Director, Defence Therapeutics Inc.

    Full interview

     

    BioNTech: Dominating the German biotech sector

    A few years ago, BioNTech could be mentioned in the same breath as Qiagen, CureVac or Morphosys. Today, the Mainz-based company towers above them all. The success of the Corona vaccine has given the Company a dominant market position. Researchers from the Rhine have around EUR 13.8 billion in cash on hand, not including outstanding receivables from partner Pfizer of around EUR 7 billion - and can therefore invest in the future like hardly any other company. But that is not all. While many biotechs have to raise capital through equity financing, BioNTech still has billions of euros in vaccines. According to Handelsblatt, BioNTech currently has a turnover of around EUR 36 billion, which is two and a half times as much as the entire German biotech sector. When looking to the future, these starting conditions are outstanding: BioNTech can invest in research at a time when many biotechs are having to tighten their belts due to poor financing conditions - and should further expand its supremacy.

    Established pharmaceutical companies like Bayer are also likely to look south along the Rhine with envy. While Bayer seems torn between its seed division and a stronger commitment to the health sector, at BioNTech, everything revolves around the fight against cancer. Nevertheless, there are also positive developments at Bayer: In the past quarters, Bayer stepped on the cost brakes, expanded its sustainability strategy and moved a stroke drug into a clinical phase III study. Add to that a dividend yield of more than 4% - this is pleasing for conservative investors, but the payout also shows that Bayer's organic growth potential seems limited.

    Bayer: Business seems saturated

    The pure comparison between Bayer and BioNTech favours the Mainz-based company. But Bayer is also solidly positioned - only the perspective for growth could be better in the comparatively saturated business with seeds and health products. The situation is different at BioNTech: its portfolio includes several blockbusters in the field of cancer alone - no wonder the Company is already valued at almost EUR 30 billion. An alternative to BioNTech with a much lower market capitalisation in the low three-digit million range could be the share of Defence Therapeutics. With Accum™, the Canadians have a versatile technology for transporting active agents into diseased cells in their portfolio. Several Phase I trials are expected to be launched in the coming quarters alone.

    Defence Therapeutics: Accum™ as a sought-after multi-tool

    The projects of Defence Therapeutics involve therapeutic vaccines against various types of cancer, the use of Accum™ in a potentised variant under the AccuTOX™ brand as a chemotherapeutic agent, and a protein-based vaccine against the HP virus, which can trigger cervical cancer. Defence Therapeutics has advanced all projects in parallel in the past months and gained prominent support in various areas. For example, the renowned City of Hope hospital in the Los Angeles area is accompanying the application process for clinical trials of AccuTOX™, and the well-known Canadian biotech incubator CQDM, which is associated with large pharmaceutical companies, is jointly financing a new cancer vaccine platform with Defence.

    At a time when biotech companies, such as BioNTech, are increasingly outpacing the competition, the principle for classic pharmaceutical companies is "stick with it". Companies such as AstraZeneca have already made acquisitions in recent months and taken over innovative biotech companies. As with Defence Therapeutics, the focus was primarily on innovative processes such as mRNA or drug delivery. Since Defence Therapeutics' technology is considered highly flexible, the Canadians could also come into the focus of large corporations. Defence has already convinced the French state-owned group Orano and announced a cooperation in the field of nuclear medicine a few weeks ago - here, too, Accum™ is expected to showcase its capabilities.


    Investors are currently spoilt for choice. The only thing that seems certain is that biotech companies have growth on their side thanks to innovative technology compared to classic pharmaceutical companies. While the valuations of BioNTech already seem ambitious, the share price of Defence Therapeutics still contains a fair amount of scepticism. For speculative investors, however, it is worth taking a closer look at the up-and-coming growth stock, which was only recently included in the CSE 25 Index.


    Conflict of interest

    Pursuant to §85 of the German Securities Trading Act (WpHG), we point out that Apaton Finance GmbH as well as partners, authors or employees of Apaton Finance GmbH (hereinafter referred to as "Relevant Persons") may hold shares or other financial instruments of the aforementioned companies in the future or may bet on rising or falling prices and thus a conflict of interest may arise in the future. The Relevant Persons reserve the right to buy or sell shares or other financial instruments of the Company at any time (hereinafter each a "Transaction"). Transactions may, under certain circumstances, influence the respective price of the shares or other financial instruments of the Company.

    In addition, Apaton Finance GmbH is active in the context of the preparation and publication of the reporting in paid contractual relationships.

    For this reason, there is a concrete conflict of interest.

    The above information on existing conflicts of interest applies to all types and forms of publication used by Apaton Finance GmbH for publications on companies.

    Risk notice

    Apaton Finance GmbH offers editors, agencies and companies the opportunity to publish commentaries, interviews, summaries, news and the like on news.financial. These contents are exclusively for the information of the readers and do not represent any call to action or recommendations, neither explicitly nor implicitly they are to be understood as an assurance of possible price developments. The contents do not replace individual expert investment advice and do not constitute an offer to sell the discussed share(s) or other financial instruments, nor an invitation to buy or sell such.

    The content is expressly not a financial analysis, but a journalistic or advertising text. Readers or users who make investment decisions or carry out transactions on the basis of the information provided here do so entirely at their own risk. No contractual relationship is established between Apaton Finance GmbH and its readers or the users of its offers, as our information only refers to the company and not to the investment decision of the reader or user.

    The acquisition of financial instruments involves high risks, which can lead to the total loss of the invested capital. The information published by Apaton Finance GmbH and its authors is based on careful research. Nevertheless, no liability is assumed for financial losses or a content-related guarantee for the topicality, correctness, appropriateness and completeness of the content provided here. Please also note our Terms of use.


    Der Autor

    Nico Popp

    At home in Southern Germany, the passionate stock exchange expert has been accompanying the capital markets for about twenty years. With a soft spot for smaller companies, he is constantly on the lookout for exciting investment stories.

    About the author



    Related comments:

    Commented by Fabian Lorenz on July 11th, 2025 | 07:20 CEST

    Biotech takeover merry-go-round picks up speed! BioNTech, Evotec, Merck, and BioNxt Solutions!

    • Biotechnology
    • Biotech
    • Pharma

    The takeover merry-go-round is spinning faster again in the biotech sector. The latest example is Merck's acquisition of Verona Pharma. The US group is paying USD 10 billion for the deal. BioNxt Solutions would be significantly cheaper to acquire at present. The Company aims to make it easier to take medication with melt films, skin patches, and tablets. In addition, it has now announced an exciting platform. The goal is to develop smarter chemotherapy, which, in turn, could create a billion-dollar market. And what are BioNTech and Evotec doing? Things have quieted down a bit at the German biotech leader following its billion-dollar deal with Bristol-Myers Squibb. However, analysts recommend buying the stock. Evotec, on the other hand, is languishing at around EUR 7. Can the quarterly figures provide new impetus for the struggling stock?

    Read

    Commented by Nico Popp on July 10th, 2025 | 07:25 CEST

    Small-cap disrupts billion-dollar market: Johnson & Johnson, Merck KGaA, and NetraMark

    • Biotechnology
    • Biotech
    • AI
    • healthtech

    When it comes to making people healthy, progress is what matters most. New drugs must be better and safer than old ones. To ensure that these requirements are met, comprehensive testing procedures are carried out by drug regulatory authorities. However, despite ever-expanding knowledge and modern methods, almost 90% of clinical trials still fail. When considering that the development of a drug costs an average of USD 2.6 billion and usually takes more than ten years, it becomes clear what a risk biotech companies and pharmaceutical multinationals are taking. This is precisely where NetraMark's business model comes in, offering the entire industry unparalleled leverage.

    Read

    Commented by Armin Schulz on July 10th, 2025 | 07:15 CEST

    How BioNTech, PanGenomic Health, and Pfizer are using artificial intelligence to cut costs and boost returns

    • Biotechnology
    • healthtech
    • Biotech
    • AI

    Digitalization is revolutionizing the biotechnology and pharmaceutical industries. Artificial intelligence sifts through billions of pieces of medical data in real time, accelerating drug development by years. This is also demonstrated by the new alliance between Moderna and Google Cloud, which are jointly developing an AI platform for customized mRNA cancer therapies. These technologies reduce production costs by up to 40% and generate disruptive return opportunities. At the same time, personalized medicine is opening up billion-dollar markets. Three companies are turning to artificial intelligence to boost their returns: BioNTech, PanGenomic Health, and Pfizer.

    Read